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This article is a comment on Ofra Golan and Paul Hansen’s framework for health technology prioritization that they
suggest could be developed and used by the committee selecting new technologies for Israel’s health basket.
Although Golan and Hansen should be commended for the innovative way they have started to explore these
issues, more work need to be done to take proper account of opportunity costs.In this issue Ofra Golan and Paul Hansen present a
framework for health technology prioritization, and
some illustrative cases, that they suggest could be deve-
loped and used by the committee selecting new technolo-
gies for Israel’s health basket [1]. The framework, they say,
is based explicitly on value for money that enables explicit
inclusion of information related to health benefits, equity
benefits, quality of evidence, health care costs and other
“X-factors” that may be of relevance for priority setting
among new interventions being considered for priority
among essential services. Such a framework is urgently
needed, not only in Israel, but also in any system that seek
to improve priority setting in an analytic, systematic, and
transparent way.
A key motivation for the proposed framework is the
need to develop a comprehensive framework that can
handle all criteria at the same time, allow for uncertainty
or lack of evidence on cost and outcomes, and aggregate
all information in a way that is transparent and allows
for making trade-offs between different considerations.
For example, they argue that for new technologies
there are often lack of precise estimates of clinical bene-
fits or “equity benefits”, so they devised a point-based
system assigning weights to broad categories of benefits.
For life-prolongation benefits or quality of life impro-
vements, these categories are: 1) None/Very small;
2) Small benefits; 3) Medium benefits; Large benefits.
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reproduction in any medium, provided the orlives saved; 3) Some: 51–250 lives saved; 4) Many: 251–
500 lives saved; or 5) Very many: > 500 lives saved.
After each technology has been rated on the points
system’s dimensions, the values are summed to get a
benefit score for each technology assessed. Next, the
score is mapped on the y-axis on a ‘Value for Money
(VfM) Chart’, where the x-axis shows net incremental
total costs to Israel’s health system. In addition, quality
of evidence (graded) is indicated by size of ‘bubble’ in
the chart, and possible “x-factors” by color symbols. By
looking at the chart, the decision makers could use this
information as input to further deliberations and subse-
quent decisions.
Although the underlying motivation and conceptuali-
zation is in accordance with many of the ideals of
transparent, accountable decision making [2], I am afraid
that the framework needs a stronger theoretical founda-
tion. In my view, there already exist methods for aggre-
gating costs [3], health benefits [4], and integrating
equity considerations [5] that should not so easily be
dismissed.
Consider three examples discussed in the article: traz-
tuzumab (Herceptin) used as adjuvant therapy for some
forms of breast cancer; verteporfin (Visudyne) is used to
treat a form of macula degeneration (that leads to blind-
ness); and left-ventricular assist devices for severe heart
failure. In Norway the permanent committee for quality
and priority setting has discussed all three interventions
and provided their advice. Left-ventricular assist devices
were assessed to cost about 3,4 mill shekel per QALY
(analysis not published in English), and is not prioritized
in the regular Norwegian health care system. Visudyne is
recognized as very costly but somewhat more cost. This is an Open Access article distributed under the terms of the Creative
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per QALY gained [6]) and introduced for some selected
indications. Herceptin as adjuvant therapy was found
clearly cost effective (at approx. 73 000 shekel per QALY
[7]) for selected groups and was quickly prioritized in
the Norwegian system.
Golan and Hanson analyze rand conclude, by way of
their framework, in exactly the opposite direction. They
argue it would be “understandable” if the Basket Com-
mittee decided not to fund Herceptin because the total
cost are so much higher than for Visudyne and left-
ventricular assist devices, and that it is “easy to imagine
decision-makers preferring LVAD (. . . to . . .) Visudyne”,
because it is cheaper.
The reason they reach a different conclusion is that
their framework highlights affordability (based on incre-
mental unit cost multiplied with number of patients in
need) instead of opportunity costs. This emphasis on af-
fordability is a bit problematic and lacks a clear theore-
tical foundation. For the cost of treating one patient
with LVAD one could treat many patients with breast
cancer and gain more than 40 times the QALYs gained
from LVAD.
Ethical and political trade-off must be made, but
not between health benefits and total costs (as the VfM
chart suggests). One may criticize incremental cost-
effectiveness analysis, because it in its standard form
disregards distributional concerns, but to disregard op-
portunity costs is probably not the best approach. Even
with weak evidence, it is better to aggregate health bene-
fits, as equity weighted QALYs, though modeling, than
by a point system based on imprecise categorizations of
health benefits. A better alternative could be to build
upon Health Technology Assessments, which should in-
clude cost-effectiveness analysis; incorporate distribu-
tional (and other) concerns after deliberations; and
acknowledge strength or lack of evidence explicitly [8].
So my advice to the Basket Committee is this: your
criteria for what to fund in the essential basket are
sound, but more work is needed before we have a model
that can handle all criteria at the same time, allow for
uncertainty, and aggregate all information in a way that
is transparent and theoretically sound. This said, I want
to commend Golan and Hansen for the innovative way
they have started to explore these issues. Having such a
framework in place would truly enhance the decision
making process.
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